Brand comparison

Same Active Hormone. Different Brands, Devices and Prices.

Norditropin, Genotropin, Omnitrope and Saizen are established pharmaceutical brands of somatropin.

The active hormone is the same type of 191-amino-acid protein, but the manufacturers, pen systems, formulations, presentations and prices differ.

Explore the differences, then open the individual product pages to see available strengths and current pricing.

Four-brand technical comparison

Compare the exact formulation and delivery system.

All four brands supply somatropin presentations. The following reference products are identified by country, strength and documentation date. Compare the named presentation and its country-specific instructions. A similarly named pack from another market can have different specifications.

Pfizer Genotropin C carton labeled 5.3 mg (16 UI)
Photograph: international Genotropin C 5.3 mg (16 UI) carton. This is not the U.S. 5 mg cartridge.
Genotropin details →
Merck Serono Saizen carton labeled 6 mg (5.83 mg/mL)
Photograph: Saizen 6 mg (5.83 mg/mL) cartridge carton. The 12 mg and 20 mg presentations are not pictured.
Saizen details →
Sandoz Omnitrope carton labeled 10 mg/1.5 mL
Photograph: Omnitrope 10 mg/1.5 mL carton. Other strengths and market-specific injector systems are separate presentations.
Omnitrope details →
Novo Nordisk Norditropin FlexPro 10 mg carton and prefilled pen
Photograph: Norditropin FlexPro 10 mg carton and pen. FlexPro and NordiFlex are distinct named pen systems.
Norditropin details →
Exact reference presentations — country and labeling remain part of each specification
ComparisonGenotropinSaizenOmnitropeNorditropin
ManufacturerPfizerMerck Serono / EMD SeronoSandozNovo Nordisk
Reference country, presentation and labelCanadian GoQuick 5.3 mg; Pfizer monograph revised July 28, 2020 [G]Canadian 6 mg liquid cartridge; EMD Serono monograph revised June 8, 2020 [S]U.S. 10 mg/1.5 mL liquid cartridge; FDA labeling, 2025 [O]U.S. FlexPro 10 mg/1.5 mL pen; Novo Nordisk PI revised January 2026 [N]
Total somatropin: mg and IU context5.3 mg; approximately 15.9 IU at 3 IU/mg. The photographed carton marks 16 UI.6 mg; approximately 18 IU at 3 IU/mg.10 mg; approximately 30 IU at 3 IU/mg.10 mg; approximately 30 IU at 3 IU/mg.
Somatropin concentration5.3 mg/mL after reconstitution.5.83 mg/mL.Approximately 6.67 mg/mL, calculated from the labeled 10 mg/1.5 mL.Approximately 6.67 mg/mL, calculated from the labeled 10 mg/1.5 mL.
Documented liquid volume / fill informationComposition is specified per 1 mL. The Canadian GoQuick container description states 1.14 mL supplied liquid; that is not the same measure as a declared deliverable volume.1.03 mL liquid fill. The nominal glass-cartridge capacity is 3 mL, not the amount of liquid supplied.1.5 mL.1.5 mL.
Preservative typeMetacresol (m-cresol).Phenol.Phenol in this 10 mg cartridge. The U.S. 5 mg cartridge instead uses benzyl alcohol.Phenol.
Documented preservative quantity3 mg/mL in the reconstituted Canadian GoQuick formulation.3.8 mg per 6 mg cartridge in the cited Canadian monograph.4.5 mg phenol per 1.5 mL cartridge, equivalent to 3 mg/mL.4.5 mg per 1.5 mL pen, equivalent to 3 mg/mL.
Other inactive ingredients and stabilizersGlycine, mannitol, sodium dihydrogen phosphate, disodium phosphate and water for injection.Sucrose, poloxamer 188, citric acid, sodium hydroxide for pH adjustment, and water for injection.Glycine, sodium phosphate buffers, poloxamer and water for injection; sodium hydroxide/phosphoric acid may adjust cartridge pH.Histidine, mannitol, poloxamer 188, hydrochloric acid/sodium hydroxide as needed for pH adjustment, and water for injection.
Delivery systemDisposable multidose GoQuick pen containing a two-chamber powder-and-solvent cartridge.Ready-to-use liquid cartridge for a compatible reusable injector.Ready-to-use liquid cartridge with a reusable injector.Integrated disposable prefilled FlexPro pen containing ready-to-use liquid.
ReconstitutionRequired. A prefilled powder-and-solvent pen is not a ready-to-use liquid pen.Not required for the specified liquid cartridge. Historical powder/vial presentations are separate.Not required for this liquid cartridge; the U.S. 5.8 mg powder vial requires reconstitution.Not required.
Cartridge and injector compatibilityGoQuick is an integrated disposable system. The separate UK 5.3 mg cartridge uses its matching blue Genotropin Pen 5.3; U.S. Pen 5 is a distinct 5 mg system.The cited Canadian/UK liquid-cartridge labeling identifies easypod or matching aluetta systems. UK aluetta 6 is blue, aluetta 12 red and aluetta 20 yellow.U.S. 10 mg/1.5 mL cartridge: Omnitrope Pen 10. The U.S. 5 mg cartridge uses Pen 5. European SurePal cartridge systems have their own matching devices.Use the integrated labeled FlexPro pen and its specified accessories. It does not accept another brand’s cartridge. NordiFlex is a separately named pen system.
Unopened storageCanadian GoQuick: refrigerate at 2–8°C until expiry, or up to 4 weeks at ≤25°C before reconstitution. During/after that unrefrigerated period, do not return the unreconstituted product to refrigeration.Refrigerate at 2–8°C in the original package; do not freeze.Refrigerate at 2–8°C in the original carton; do not freeze.Refrigerate at 2–8°C until the printed expiry; do not freeze; protect from light.
In-use storageAfter reconstitution, refrigerate at 2–8°C and protect from light; do not freeze or shake.28 days total at 2–8°C, of which no more than 7 days may be at ≤25°C; keep the cartridge in the specified device and return it to refrigeration.Keep the cartridge in its specified pen, refrigerated at 2–8°C and protected from light.Either refrigerate at 2–8°C for up to 4 weeks, or store at ≤25°C for up to 3 weeks.
In-use shelf life4 weeks after reconstitution under the Canadian labeled storage conditions.Discard after 28 days, or if the total permitted unrefrigerated period exceeds 7 days.28 days after first use for the specified U.S. cartridges; the separate U.S. powder vial has a 21-day rule after reconstitution.4 weeks refrigerated OR 3 weeks at the labeled room-temperature limit; these are alternatives, not additive periods.
Important formulation differencesPowder plus solvent; metacresol-preserved multidose formulation. MiniQuick is a separate preservative-free single-dose presentation.Sucrose-containing liquid formulation. The 12 mg and 20 mg cartridges have different concentrations/fill volumes from the 6 mg cartridge.Preservative and stabilizer vary by strength: U.S. 5 mg has benzyl alcohol/mannitol; 10 mg has phenol/glycine.Prefilled liquid with histidine/mannitol/poloxamer. The U.S. 15 mg pen has different histidine/mannitol quantities from the 5 mg and 10 mg pens.
Practical advantagesIntegrated GoQuick avoids replacing cartridges in a reusable injector; preparation is still required.Ready-to-use cartridge; a choice of labeled compatible injection systems.Reusable injector with replaceable ready-to-use cartridges.No reconstitution or separate reusable cartridge loading for the specified FlexPro presentation.
Limitations and considerationsMatch the exact country, strength and device. The international 5.3 mg pack and U.S. 5 mg cartridge are not identical product listings.Cartridge capacity does not establish fill volume. click.easy belongs to a different historical powder presentation, not a universal Saizen cartridge system.Select the cartridge for its matching injector. A 15 mg international cartridge is not automatically compatible with a U.S. Pen 10.Do not infer equivalent pen mechanics, formulation quantities or market authorization from the Norditropin name alone.

Genotropin

Manufacturer
Pfizer
Reference country, presentation and label
Canadian GoQuick 5.3 mg; Pfizer monograph revised July 28, 2020 [G]
Total somatropin: mg and IU context
5.3 mg; approximately 15.9 IU at 3 IU/mg. The photographed carton marks 16 UI.
Somatropin concentration
5.3 mg/mL after reconstitution.
Documented liquid volume / fill information
Composition is specified per 1 mL. The Canadian GoQuick container description states 1.14 mL supplied liquid; that is not the same measure as a declared deliverable volume.
Preservative type
Metacresol (m-cresol).
Documented preservative quantity
3 mg/mL in the reconstituted Canadian GoQuick formulation.
Other inactive ingredients and stabilizers
Glycine, mannitol, sodium dihydrogen phosphate, disodium phosphate and water for injection.
Delivery system
Disposable multidose GoQuick pen containing a two-chamber powder-and-solvent cartridge.
Reconstitution
Required. A prefilled powder-and-solvent pen is not a ready-to-use liquid pen.
Cartridge and injector compatibility
GoQuick is an integrated disposable system. The separate UK 5.3 mg cartridge uses its matching blue Genotropin Pen 5.3; U.S. Pen 5 is a distinct 5 mg system.
Unopened storage
Canadian GoQuick: refrigerate at 2–8°C until expiry, or up to 4 weeks at ≤25°C before reconstitution. During/after that unrefrigerated period, do not return the unreconstituted product to refrigeration.
In-use storage
After reconstitution, refrigerate at 2–8°C and protect from light; do not freeze or shake.
In-use shelf life
4 weeks after reconstitution under the Canadian labeled storage conditions.
Important formulation differences
Powder plus solvent; metacresol-preserved multidose formulation. MiniQuick is a separate preservative-free single-dose presentation.
Practical advantages
Integrated GoQuick avoids replacing cartridges in a reusable injector; preparation is still required.
Limitations and considerations
Match the exact country, strength and device. The international 5.3 mg pack and U.S. 5 mg cartridge are not identical product listings.
Detailed Genotropin page →

Saizen

Manufacturer
Merck Serono / EMD Serono
Reference country, presentation and label
Canadian 6 mg liquid cartridge; EMD Serono monograph revised June 8, 2020 [S]
Total somatropin: mg and IU context
6 mg; approximately 18 IU at 3 IU/mg.
Somatropin concentration
5.83 mg/mL.
Documented liquid volume / fill information
1.03 mL liquid fill. The nominal glass-cartridge capacity is 3 mL, not the amount of liquid supplied.
Preservative type
Phenol.
Documented preservative quantity
3.8 mg per 6 mg cartridge in the cited Canadian monograph.
Other inactive ingredients and stabilizers
Sucrose, poloxamer 188, citric acid, sodium hydroxide for pH adjustment, and water for injection.
Delivery system
Ready-to-use liquid cartridge for a compatible reusable injector.
Reconstitution
Not required for the specified liquid cartridge. Historical powder/vial presentations are separate.
Cartridge and injector compatibility
The cited Canadian/UK liquid-cartridge labeling identifies easypod or matching aluetta systems. UK aluetta 6 is blue, aluetta 12 red and aluetta 20 yellow.
Unopened storage
Refrigerate at 2–8°C in the original package; do not freeze.
In-use storage
28 days total at 2–8°C, of which no more than 7 days may be at ≤25°C; keep the cartridge in the specified device and return it to refrigeration.
In-use shelf life
Discard after 28 days, or if the total permitted unrefrigerated period exceeds 7 days.
Important formulation differences
Sucrose-containing liquid formulation. The 12 mg and 20 mg cartridges have different concentrations/fill volumes from the 6 mg cartridge.
Practical advantages
Ready-to-use cartridge; a choice of labeled compatible injection systems.
Limitations and considerations
Cartridge capacity does not establish fill volume. click.easy belongs to a different historical powder presentation, not a universal Saizen cartridge system.
Detailed Saizen page →

Omnitrope

Manufacturer
Sandoz
Reference country, presentation and label
U.S. 10 mg/1.5 mL liquid cartridge; FDA labeling, 2025 [O]
Total somatropin: mg and IU context
10 mg; approximately 30 IU at 3 IU/mg.
Somatropin concentration
Approximately 6.67 mg/mL, calculated from the labeled 10 mg/1.5 mL.
Documented liquid volume / fill information
1.5 mL.
Preservative type
Phenol in this 10 mg cartridge. The U.S. 5 mg cartridge instead uses benzyl alcohol.
Documented preservative quantity
4.5 mg phenol per 1.5 mL cartridge, equivalent to 3 mg/mL.
Other inactive ingredients and stabilizers
Glycine, sodium phosphate buffers, poloxamer and water for injection; sodium hydroxide/phosphoric acid may adjust cartridge pH.
Delivery system
Ready-to-use liquid cartridge with a reusable injector.
Reconstitution
Not required for this liquid cartridge; the U.S. 5.8 mg powder vial requires reconstitution.
Cartridge and injector compatibility
U.S. 10 mg/1.5 mL cartridge: Omnitrope Pen 10. The U.S. 5 mg cartridge uses Pen 5. European SurePal cartridge systems have their own matching devices.
Unopened storage
Refrigerate at 2–8°C in the original carton; do not freeze.
In-use storage
Keep the cartridge in its specified pen, refrigerated at 2–8°C and protected from light.
In-use shelf life
28 days after first use for the specified U.S. cartridges; the separate U.S. powder vial has a 21-day rule after reconstitution.
Important formulation differences
Preservative and stabilizer vary by strength: U.S. 5 mg has benzyl alcohol/mannitol; 10 mg has phenol/glycine.
Practical advantages
Reusable injector with replaceable ready-to-use cartridges.
Limitations and considerations
Select the cartridge for its matching injector. A 15 mg international cartridge is not automatically compatible with a U.S. Pen 10.
Detailed Omnitrope page →

Norditropin

Manufacturer
Novo Nordisk
Reference country, presentation and label
U.S. FlexPro 10 mg/1.5 mL pen; Novo Nordisk PI revised January 2026 [N]
Total somatropin: mg and IU context
10 mg; approximately 30 IU at 3 IU/mg.
Somatropin concentration
Approximately 6.67 mg/mL, calculated from the labeled 10 mg/1.5 mL.
Documented liquid volume / fill information
1.5 mL.
Preservative type
Phenol.
Documented preservative quantity
4.5 mg per 1.5 mL pen, equivalent to 3 mg/mL.
Other inactive ingredients and stabilizers
Histidine, mannitol, poloxamer 188, hydrochloric acid/sodium hydroxide as needed for pH adjustment, and water for injection.
Delivery system
Integrated disposable prefilled FlexPro pen containing ready-to-use liquid.
Reconstitution
Not required.
Cartridge and injector compatibility
Use the integrated labeled FlexPro pen and its specified accessories. It does not accept another brand’s cartridge. NordiFlex is a separately named pen system.
Unopened storage
Refrigerate at 2–8°C until the printed expiry; do not freeze; protect from light.
In-use storage
Either refrigerate at 2–8°C for up to 4 weeks, or store at ≤25°C for up to 3 weeks.
In-use shelf life
4 weeks refrigerated OR 3 weeks at the labeled room-temperature limit; these are alternatives, not additive periods.
Important formulation differences
Prefilled liquid with histidine/mannitol/poloxamer. The U.S. 15 mg pen has different histidine/mannitol quantities from the 5 mg and 10 mg pens.
Practical advantages
No reconstitution or separate reusable cartridge loading for the specified FlexPro presentation.
Limitations and considerations
Do not infer equivalent pen mechanics, formulation quantities or market authorization from the Norditropin name alone.
Detailed Norditropin page →

IU equivalents use approximately 3 IU per mg of ordinary somatropin. Calculated concentration is identified as calculated. These are product-content comparisons, not dose instructions. Liquid fill, solvent volume, deliverable volume and the capacity of the glass cartridge are different quantities.

Presentation-specific differences

One brand can have more than one formulation.

BrandCountry and presentationStrength and liquid informationFormulation, device and storage distinction
GenotropinU.S. multidose 5 / 12 mg5 / 12 mg per 1 mL deliverable; 5 / 12 mg/mL after reconstitutionMetacresol 3 mg/mL; matching Pen 5 / Pen 12; 28 days at 2–8°C after reconstitution. [GU]
GenotropinU.S. MiniQuick0.2–2 mg in 0.2 mg steps; 0.25 mL deliverable per single-dose devicePreservative-free; reconstitution required. Before mixing: 2–8°C or up to 3 months ≤25°C; after mixing: up to 24 hours at 2–8°C if needed. [GU]
GenotropinUK 5.3 mg5.3 mg/mL after reconstitution; 1 mL solvent statedMetacresol listed; blue Pen 5.3 or GoQuick; 28 days at 2–8°C after reconstitution. [GK]
SaizenCanada 6 / 12 / 20 mg liquid5.83 / 8 / 8 mg/mL; liquid fills 1.03 / 1.50 / 2.50 mLPhenol amounts respectively 3.8 / 5.6 / 9.3 mg per cartridge in the June 2020 monograph. These quantities belong to that Canadian reference. [S]
SaizenUK 6 / 12 / 20 mg liquid6 mg/1.03 mL; 12 mg/1.5 mL; 20 mg/2.5 mLPhenol, sucrose and poloxamer 188 listed. Use easypod or matching aluetta; 28 days total including up to 7 days ≤25°C. [SK]
SaizenCanada historical 5 mg powder vialSeparate powder/diluent presentationBacteriostatic diluent contains benzyl alcohol. Its diluent-dependent storage rules are different from liquid cartridges. [S]
OmnitropeU.S. 5 mg/1.5 mL liquidApproximately 3.33 mg/mL, calculatedBenzyl alcohol 13.5 mg/cartridge (9 mg/mL); mannitol; Pen 5; refrigerated in-use limit 28 days. [O]
OmnitropeU.S. 10 mg/1.5 mL liquidApproximately 6.67 mg/mL, calculatedPhenol 4.5 mg/cartridge (3 mg/mL); glycine; Pen 10; refrigerated in-use limit 28 days. [O]
OmnitropeEU 5 / 10 / 15 mg liquidLabeled 3.3 / 6.7 / 10 mg/mL; 1.5 mL each; 15 / 30 / 45 IU respectively5 mg: benzyl alcohol/mannitol; 10 mg: phenol/glycine; 15 mg: phenol/sodium chloride. Specific cartridge presentations match Omnitrope Pen 5/10 or SurePal 5/10/15; retain labeled pairing. [OE]
OmnitropeU.S. 5.8 mg powder vial5 mg/mL after reconstitutionSupplied diluent contains 1.5% benzyl alcohol. This is not a liquid cartridge; refrigerated use after reconstitution is limited to 21 days. [O]
NorditropinU.S. FlexPro 5 / 10 / 15 mgEach contains 1.5 mL; approximately 3.33 / 6.67 / 10 mg/mL, calculatedEach pen contains 4.5 mg phenol; histidine/mannitol quantities differ at 15 mg. Ready-to-use prefilled pens. [N]
NorditropinCanada NordiFlex 5 / 10 / 15 mg, 2018 referenceEach contains 1.5 mL; 4.5 mg phenol per penDifferent named device system from FlexPro; do not infer pen interchangeability from shared brand or fill volume. [NC]
At-a-glance

What actually changes.

DimensionGenotropinSaizenOmnitropeNorditropin
Active drugSomatropinSomatropinSomatropinSomatropin
ManufacturerPfizerMerck / EMD SeronoSandozNovo Nordisk
Preservativem-Cresol (metacresol) in 5 mg and 12 mg multidose cartridges; MiniQuick is preservative-freePhenol in current 6 mg / 12 mg / 20 mg cartridge formulations in current non-U.S. manufacturer labelingDepends on presentation: U.S. 5 mg cartridge uses benzyl alcohol; U.S. 10 mg cartridge uses phenolPhenol in current Norditropin FlexPro multidose pens
Other inactive ingredientsGlycine, mannitol, phosphate buffers and water; multidose cartridges also contain m-cresol after reconstitutionSucrose, poloxamer 188, citric acid, sodium hydroxide for pH adjustment and waterPhosphate buffers, poloxamer 188, plus mannitol in the 5 mg cartridge or glycine in the 10 mg cartridge, and waterHistidine, mannitol, poloxamer 188, hydrochloric acid / sodium hydroxide for pH, water
Typical device conceptTwo-chamber cartridge systems and MiniQuick optionsMarket-specific cartridge/device systemsReusable pen + cartridge in current U.S. systemPrefilled FlexPro pen
What patients noticeMixing/reconstitution options and MiniQuick travel characteristicsPresentation/device availability varies by marketCartridge loading and reusable deviceReady-to-use pen simplicity
StorageCartridge and MiniQuick rules differFollow exact presentation instructionsProduct-specific cartridge refrigeration; U.S. opened cartridges have a 28-day ruleProduct-specific refrigerated and in-use rules
Regulatory nuanceCurrent Pfizer U.S. labeling plus market-specific presentations elsewhereU.S. approval history and Canadian/UK liquid-cartridge labeling are distinct; presentation and authorization are country-specific.U.S. and Mexican presentation sets can differCurrent U.S. FDA-labeled product; Mexican presentations separately regulated
Published product-page reference pricing5.3 mg from $420 each in quantity tier6 mg from $450 each in quantity tier10 mg from $610 each in quantity tier10 mg from $770
Formulation comparison

What else is in the injection besides somatropin?

The active hormone can be the same while the preservative, stabilizers, surfactants and pH-control ingredients differ. Those differences do not make one brand inherently stronger, but they can matter for device design, shelf life, handling, allergy or tolerability, and patient preference.

Norditropin® FlexPro / NordiFlex

Preservative: Phenol.

Other inactive ingredients: Histidine, mannitol, poloxamer 188, hydrochloric acid / sodium hydroxide as needed for pH adjustment, and water for injection.

Why they are there: phenol provides antimicrobial preservation in the multidose pen; mannitol helps stabilize/adjust tonicity; histidine helps buffer the formulation; poloxamer 188 is a surfactant that helps protect the protein; acid/base ingredients control pH.

Omnitrope®

Preservative depends on strength: the current U.S. 5 mg/1.5 mL cartridge contains benzyl alcohol, while the 10 mg/1.5 mL cartridge contains phenol.

5 mg cartridge: benzyl alcohol, mannitol, poloxamer 188, dibasic and monobasic sodium phosphate, water.

10 mg cartridge: phenol, glycine, poloxamer 188, dibasic and monobasic sodium phosphate, water.

Why this matters: Omnitrope is a good example of why the exact presentation matters; two strengths under the same brand can use different preservatives and stabilizers.

Genotropin®

Preservative: m-Cresol (metacresol) in the 5 mg and 12 mg single-patient multidose cartridges. GENOTROPIN MiniQuick is labeled without preservative.

Other inactive ingredients: Glycine, mannitol, sodium phosphate buffer ingredients and water for injection.

Why it is different: the 5 mg and 12 mg cartridges are two-chamber systems; the preservative is present in the reconstituted multidose product. MiniQuick is single-dose, so it does not need the same multidose preservative system.

Saizen®

Preservative: Phenol in current 6 mg, 12 mg and 20 mg cartridge formulations shown in current manufacturer labeling outside the U.S.

Other inactive ingredients: Sucrose, poloxamer 188, citric acid, sodium hydroxide for pH adjustment and water for injection.

Why they are there: sucrose helps stabilize the protein, poloxamer 188 acts as a surfactant, and the citric-acid / sodium-hydroxide system controls pH. Saizen presentation details are market-specific, so the exact local package insert should be checked.

Plain-English takeaway: Somatropin is the active medicine. Preservatives such as phenol, m-cresol and benzyl alcohol help control microbial growth in multidose systems. Stabilizers such as mannitol, sucrose and glycine help keep the protein formulation stable. Poloxamer 188 helps protect the protein at surfaces and during handling. Phosphate, histidine and citrate systems help keep pH in the intended range. These formulation differences are real, but they are not evidence that one brand is inherently “stronger.”
Label sources used for this comparison
  • U.S. DailyMed / FDA labeling for Norditropin FlexPro.
  • U.S. DailyMed / FDA labeling for Omnitrope cartridges and vial presentations.
  • U.S. DailyMed / FDA labeling for Genotropin 5 mg, 12 mg and MiniQuick.
  • Canadian EMD Serono monograph and country-specific Merck labeling for cartridge composition; Saizen presentations vary by country.
Cross-brand FAQ

Questions about formulations and devices.

What's the difference between Norditropin FlexPro and NordiFlex?

Both contain Norditropin somatropin manufactured by Novo Nordisk. The active hormone is the same. The difference is the pen delivery system and its controls.

A 10 mg pen contains 10 mg of active somatropin regardless of which of these two Norditropin pen systems is used. Neither offers a more powerful version of HGH.

The delivery devices and instructions can differ, so use the correct system for the specific presentation.

Are all somatropin brands the same hormone?

They use somatropin as the active hormone, but the products are not literally identical in device, concentration, inactive ingredients, dose-selection mechanics, storage or presentation.

Is one HGH brand stronger than another?

Brand name does not make one product inherently stronger. A larger total-mg device can contain more medication, but the administered dose is whatever the physician prescribes.

Can one brand work better for some patients?

Practical fit can differ because of device design, dose increments, tolerability, handling, adherence, availability and cost. That is different from claiming one brand's somatropin molecule is inherently more powerful.

Do preservatives and excipients differ?

Yes—sometimes even between strengths of the same brand. Norditropin FlexPro uses phenol; current U.S. Omnitrope uses benzyl alcohol in the 5 mg cartridge and phenol in the 10 mg cartridge; Genotropin 5 mg and 12 mg multidose cartridges use m-cresol while MiniQuick is preservative-free; current Saizen cartridge labeling lists phenol. The stabilizers, surfactants and pH buffers also differ, which is why the exact presentation should be compared rather than treating every somatropin product as compositionally identical.

Can I switch brands and keep the same dose?

Do not assume that switching devices or concentrations is a purely commercial change. The prescribing clinician should review the exact product and dosing instructions.

Why do prices vary so much?

Manufacturer, device, country, supply chain, package size, availability and insurance or market conditions can all affect price.

Choose by question

Go directly to the product detail.

Norditropin

10 vs 15 mg, FlexPro, needles, refrigeration, mg vs IU.

Open Norditropin →

Omnitrope

Cartridges, reusable pen, U.S. vs Mexico presentations, biosimilar terminology.

Open Omnitrope →

Genotropin

Pen 5 / Pen 12, MiniQuick, mixing, travel and storage.

Open Genotropin →

Saizen

Mexican presentations, U.S. status and authenticity.

Open Saizen →

Technical references

  1. [G] Pfizer Canada Genotropin monograph, revised July 28, 2020; composition pp.42–43, storage pp.41–42.
  2. [GU] Pfizer U.S. Genotropin prescribing information, sections 2.3, 11 and 16.2.
  3. [GK] Pfizer UK Genotropin 5.3 mg SmPC, revised May 2024, sections 2 and 6.
  4. [S] EMD Serono Canadian Saizen monograph, revised June 8, 2020, pp.44–46 and 81.
  5. [SK] Merck UK Saizen 5.83 mg/mL and 8 mg/mL SmPCs, revised September 2026, sections 2, 6.1, 6.3, 6.4 and 6.6.
  6. [O] FDA Omnitrope prescribing information, 2025, sections 2.3, 11 Table 4 and 16.2.
  7. [OE] EMA Omnitrope product information, presentation-specific sections 2 and 6.
  8. [N] Novo Nordisk U.S. Norditropin prescribing information, revised January 2026, sections 11 and 16.
  9. [NC] Canadian Norditropin NordiFlex monograph, approved April 24, 2018, p.38.

These country-specific records describe the named reference presentations. Equal milligrams of active somatropin do not establish identical excipients, interchangeable cartridges or equivalent instructions. Preservative and concentration alone do not establish medical superiority.